Articles about advances in treatment of mesothelioma with chemotherapy, including new agents in the management of advanced mesothelioma, standard and novel systemic treatments; and sequential and combination chemotherapy.

Standard therapy for the treatment of malignant pleural mesothelioma.
Vogelzang NJ. Nevada Cancer Institute, Las Vegas, NV 89135, USA. nvogelzang@nvcancer.org

New agents in the management of advanced mesothelioma.
Vogelzang NJ, Porta C, Mutti L. Nevada Cancer Institute, Las Vegas, NV 89135, USA. nvogelza@nvcancer.org

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Heidelberg University Medical Center, Mannheim, Germany. Prof.Manegold@t-online.de

Multimodality therapy in mesothelioma: role of chemotherapy.
Vogelzang NJ. Nevada Cancer Institute, 10,000 West Charleston Boulevard, Suite 260, Las Vegas, NV 89135, USA. nvogelza@nvcancer.org

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. University of Chicago, Cancer Research Center, 5841 South Maryland Ave, Chicago, IL 60637, USA. nvogelza@medicine.bsd.uchicago.edu.

Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
Pinto C, Marino A, De Pangher Manzini V, Benedetti G, Galetta D, Mazzanti P, Del Conte G, dell'Amore D, Piana E, Giaquinta S, Lopez M, Martoni A. Unit of Medical Oncology, S. Orsola-Malpighi Hospital, Via Albertoni 15, 40138 Bologna, Italy. cpinto@aosp.bo.it

Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
Pinto C, Marino A, Guaraldi M, Melotti B, Piana E, Martoni A, Pannuti F. Division of Medical Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy. cpinto@orsola-malpghi.med.unibo.it

Systemic treatments for mesothelioma: standard and novel.
Kindler HL. Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA. hkindler@medicine.bsd.uchicago.edu

Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.
Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schönfeld N, Serke M. Respiratory Diseases Clinic Heckeshorn, Department of Pneumology, HELIOS Klinikum Emil von Behring, Berlin, Germany. torsten.bauer@helios-kliniken.de.